These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7872061)

  • 21. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment.
    Weller S; Jones LS; Lou Y; Peppercorn A; Ng-Cashin J
    Antimicrob Agents Chemother; 2013 Jul; 57(7):2967-71. PubMed ID: 23587959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Removal of clodronate by haemodialysis in end-stage renal disease patients.
    Beigel AE; Rienhoff E; Olbricht CJ
    Nephrol Dial Transplant; 1995 Dec; 10(12):2266-8. PubMed ID: 8808223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of disodium clodronate in human plasma and urine using gas-chromatography-nitrogen-phosphorous detections: validation and application in pharmacokinetic study.
    Muntoni E; Canaparo R; Della Pepa C; Serpe L; Casale F; Barbera S; Romano P; Zara GP; Eandi M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jan; 799(1):133-9. PubMed ID: 14659445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of renal impairment on the pharmacokinetics of zalcitabine.
    Bazunga M; Tran HT; Kertland H; Chow MS; Massarella J
    J Clin Pharmacol; 1998 Jan; 38(1):28-33. PubMed ID: 9597556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Famotidine disposition in children and adolescents with chronic renal insufficiency.
    Maples HD; James LP; Stowe CD; Jones DP; Hak EB; Blumer JL; Vogt B; Wilson JT; Kearns GL; Wells TG;
    J Clin Pharmacol; 2003 Jan; 43(1):7-14. PubMed ID: 12520622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skeletal deposition of clodronate is related to parathyroid function and bone turnover in dialysis patients.
    Saha H; Ala-Houhala I; Ylitalo P; Kleimola T; Pasternack A
    Clin Nephrol; 2002 Jul; 58(1):47-53. PubMed ID: 12141406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of carumonam in patients with renal insufficiency.
    Horber F; Egger HJ; Weidekamm E; Dubach UC; Frey FJ; Probst PJ; Stoeckel K
    Antimicrob Agents Chemother; 1986 Jan; 29(1):116-21. PubMed ID: 3729324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isepamicin disposition in subjects with various degrees of renal function.
    Halstenson CE; Kelloway JS; Affrime MB; Lin CC; Teal MA; Shapiro BE; Awni WM
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2382-7. PubMed ID: 1804011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The absolute bioavailability of clodronate from two different oral doses.
    Villikka K; Perttunen K; Rosnell J; Ikävalko H; Vaho H; Pylkkänen L
    Bone; 2002 Sep; 31(3):418-21. PubMed ID: 12231416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disposition of famotidine in renal insufficiency.
    Halstenson CE; Abraham PA; Opsahl JA; Chremos AN; Keane WF; Matzke GR
    J Clin Pharmacol; 1987 Oct; 27(10):782-7. PubMed ID: 3429684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function.
    Berenson JR; Rosen L; Vescio R; Lau HS; Woo M; Sioufi A; Kowalski MO; Knight RD; Seaman JJ
    J Clin Pharmacol; 1997 Apr; 37(4):285-90. PubMed ID: 9115053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.
    Kneer J; Tam YK; Blouin RA; Frey FJ; Keller E; Stathakis C; Luginbuehl B; Stoeckel K
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1952-7. PubMed ID: 2610506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition of minoxidil in patients with various degrees of renal function.
    Halstenson CE; Opsahl JA; Wright CE; Fleishaker JC; Andreadis NA; Sobieraj J; Matzke GR
    J Clin Pharmacol; 1989 Sep; 29(9):798-802. PubMed ID: 2808745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats.
    Laurén L; Osterman T; Karhi T
    Pharmacol Toxicol; 1991 Nov; 69(5):365-8. PubMed ID: 1839447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disposition kinetics of disopyramide in patients with renal insufficiency.
    Shen DD; Cunningham JL; Shudo I; Azarnoff DL
    Biopharm Drug Dispos; 1980; 1(3):133-40. PubMed ID: 7448340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of clodronate in patients with metastatic breast cancer.
    Pentikäinen PJ; Elomaa I; Nurmi AK; Kärkkäinen S
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):222-8. PubMed ID: 2525532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of clodronate disodium evaluated in plasma, synovial fluid and urine.
    Krueger CR; Mitchell CF; Leise BS; Knych HK
    Equine Vet J; 2020 Sep; 52(5):725-732. PubMed ID: 32003488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disposition of guanadrel in subjects with normal and impaired renal function.
    Halstenson CE; Opsahl JA; Abraham PA; Schwenk MH; Andreadis NA; Antal EJ; Matzke GR
    J Clin Pharmacol; 1989 Feb; 29(2):128-32. PubMed ID: 2715368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction.
    Krakamp B; Tanswell P; Vogel H; Bozler G
    Eur J Clin Pharmacol; 1989; 36(1):75-8. PubMed ID: 2917593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.